HLB starts Phase 3 clinical trials for ophthalmic disease treatment in US
Jae-Young Han
Apr 13, 2023 (Gmt+09:00)
South Korea's pharmaceutical company HLB Therapeutics Co. announced on Thursday that it has started patient administration of "RGN-259," a treatment for neurotrophic keratopathy, which is currently in development through its US subsidiary Regentry in Phase 3 clinical trials in the United States.
The company is developing RGN-259 as an eye-drop treatment for both dry eye syndrome and neurotrophic keratopathy.
The Phase 3 trial in the US involves administering RGN-259 to 70 patients for four weeks.
The company plans to conduct clinical trials of the same substance in Europe as well in order to shorten the approval period.